LGC has acquired the laboratory automation company Douglas Scientific from Kingdom Enterprises for an undisclosed price, the companies said today, in a deal designed to expand the buyer’s high-throughput PCR offerings.

Douglas Scientific provides high-throughput PCR and quantitative PCR (qPCR) platforms, as well as consumables, to markets that include agbio and clinical research laboratories. The company’s offerings include:

  • Nexar®, an ultra-high-throughput platform for endpoint genotyping that, according to the company, is used by the majority of the world’s largest seed organizations, as well as customers in other markets such as livestock breeders, food testing, and veterinary diagnostics.
  • The IntelliQube® automated mid- to high-throughput instrument for both endpoint and qPCR.
  • Array Tape consumable technology for high-throughput automated genotyping and qPCR on both the Nexar and IntelliQube platforms.

The acquisition will enable LGC to offer a broader range of high-throughput genotyping and qPCR instrumentation, plus proprietary DNA extraction solutions, PCR assays, and reagents and associated consumables, the companies said.

“Customers will benefit from the unique synergies between our two organizations, including: combined workflow solutions for extraction, genotyping and gene expression with optimized application protocols utilizing LGC proprietary KASP® and KlearKall™ PCR mastermix reagents together with our Biosearch BHQ® and BHQplus® probes,” LGC Managing Director Giulio Cerroni said in a statement.

He added that the combined company will benefit from LGC’s global presence to offer customers access to the SNPline™, Nexar®, and IntelliQube® platforms worldwide.

“We are looking forward to joining the LGC team, expanding into new markets, and developing new offerings that will leverage our strong engineering capabilities and LGC’s proven chemistries,” added Dan Malmstrom, President and COO of Douglas Scientific.

Previous articleMachine Learning Puts a Bow on Enhancer-Promoter Predictions
Next articleFDA Approves First Monoclonal Antibody Biosimilar